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Complement is crucial in the
pathogenesis of ANCA-associated
vasculitis
Cees G.M. Kallenberg1 and Peter Heeringa2
Renal lesions in ANCA-associated vasculitis (AAV) show an absence
or paucity of immune deposits. Therefore, complement was not
considered a major pathogenic factor. Data from an animal model of
AAV, however, suggest involvement of the alternative pathway of
complement. The paper by Gou et al. demonstrates activation also of
the alternative and final common pathways in patients with AAV. Thus,
the complement system might be a target for treatment in human AAV.
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The ANCA-associated vasculitides
(AAVs) are characterized by systemic
vasculitis in combination with the
presence of anti-neutrophil cytoplasmic
antibodies (ANCA) directed to either
proteinase 3 (PR3) or myeloperoxidase
(MPO). They include granulomatosis
with polyangiitis (GPA), microscopic
polyangiitis and its renal-limited form,
and Churg–Strauss syndrome. The fre-
quent involvement of the kidney is
histologically apparent as necrotizing
crescentic glomerulonephritis. In con-
trast to other forms of glomerulone-
phritis, deposits of immunoglobulins
and complement, as studied by direct
immunofluorescence of renal biopsies,
are absent or scanty. Therefore, glomer-
ulonephritis is designated as pauci-
immune in the AAVs, and complement
was suggested not to play a major role
in the immunopathogenesis of these
conditions. Nevertheless, a detailed
study by Haas and Eustace1 on 126
renal biopsies of patients with
necrotizing crescentic glomerulone-
phritis with positive ANCA serology
or necrotizing arteritis in the absence of
known ANCA results showed glome-
rular immune deposits by electron
microscopy in 68 biopsies (54%). The
majority of the latter biopsies stained
for at least one immunoglobulin or
complement factor, and nearly half of
the biopsies negative by electron
microscopy showed positive immuno-
fluorescence findings, although immu-
nofluorescent staining was relatively
weak in almost all biopsies. Despite
these findings, AAVs were not conside-
red immune complex-mediated condit-
ions, and ANCA-induced neutrophil
activation was presented as the key
factor in their immunopathogenesis.2
Data from an animal model of
MPO-ANCA vasculitis, however, sug-
gested a critical role for complement in
the induction of necrotizing crescentic
glomerulonephritis.3 In this model,
anti-MPO antibodies are induced in
MPO-deficient mice and transferred
into wild-type mice, resulting in
crescentic glomerulonephritis. When
the recipient mice were deficient in
complement C5 or factor B of the
alternative pathway of complement, no
disease developed. However, recipient
mice deficient in C4, a factor of the
classical and mannose-binding lectin
pathways of complement, developed
glomerulonephritis to the same extent
as wild-type mice. When mice were
pretreated with a C5-inhibiting mono-
clonal antibody, the development of
lesions could be prevented. Treatment
starting one day after disease induction
strongly attenuated glomerular crescent
formation.4 These experimental data
suggest that the alternative pathway
of complement is involved in the
pathogenesis of ANCA-associated
glomerulonephritis and that interven-
ing in complement activation can
prevent disease progression.
IS COMPLEMENT INVOLVED IN HUMAN
AAV?
As mentioned, the AAVs are designated
as pauci-immune conditions, some-
what suggesting that immunoglobulins
and complement are not directly in-
volved in immunopathogenesis. Preli-
minary data from China, however,
showed that factor B and properdin,
components of the alternative pathway
of complement, could be detected in
glomeruli and small vessels of seven
patients with pauci-immune AAV.5
These factors colocalized with C3d
and the membrane attack complex,
suggesting that activation of the alter-
native pathway leads to renal damage.
In contrast, C4d and mannose-binding
lectin were not detected, indicating that
both the classical pathway and the
mannose-binding lectin pathway are
not involved and excluding AAV as an
immune complex-mediated disease. A
second study by the same group on 12
patients with ANCA-negative pauci-
immune crescentic glomerulonephritis,
however, did detect C4d in eight and
mannose-binding lectin in six renal
biopsies.6 In this issue of Kidney
International, the same group of
authors has, for the first time,
analyzed plasma levels of complement
components in 66 patients with active
AAV and 54 with AAV in remission.7
The findings are consistent with
systemic activation of the alternative
pathway of complement as demon-
strated by increased levels of factor Bb
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and C3a following activation and
decreased levels of properdin, possibly
due to consumption. Furthermore, the
final common pathway was activated, as
reflected by increased levels of C5a and
C5b-9, suggesting that complement
activation is involved in the immune
effector phase of AAV. This is also
suggested by a decrease of activation
factors during remission and the
correlation of plasma levels of factor Bb
during active disease with a score for
clinical disease activity (Birmingham
Vasculitis Activity Score) and with the
proportion of (cellular) crescents in the
renal biopsy. Somewhat surprisingly,
the authors found increased levels of
C4d in patients with active AAV, which
did not decrease during remission. They
speculate that the strong inflammatory
process in AAV leads to accumulation of
apoptotic and necrotic cells with
increased production of C4d during
their clearance. This, however, does not
explain increased levels of C4d during
remission. Otherwise, the absence of
decreased levels of C2 and C4 during
active disease (these levels were even
increased) argues against consumption
of C2 and C4 during activation of
the classical and/or lectin pathway of
complement activation. These data,
being strongly supportive for a major
role of complement in AAV, should be
confirmed by others.
What are the clinical consequences
of complement activation in AAV?
As shown in their paper, Gou et al.7
observed in particular a strong increase
in plasma levels of C5a during active
AAV. The anaphylatoxin C5a has a
strong proinflammatory activity. In
relation to ANCA-induced neutrophil
activation, C5a is able to prime neutro-
phils, resulting, among others, in the
expression of proteinase 3 (PR3) on the
neutrophil membrane. Priming is a
prerequisite for ANCA-induced neutro-
phil activation, allowing PR3-ANCA
to interact with PR3 on the surface of
the neutrophil. The signaling pathways
involved in C5a priming have been
defined, and blocking of these path-
ways with inhibitors of p38 MAPK,
ERK, and PI3K decreases C5a-induced
membrane expression of PR3 and
release of lactoferrin from neutrophils
activated by PR3-ANCA following C5a
priming.8 The interaction between
C5a and its receptor on neutrophils
has, indeed, been shown to cause a
significant amplification loop for
ANCA-induced neutrophil activation.9
These observations are consistent with
a recent study by Camous and collea-
gues demonstrating that neutrophils,
stimulated by cytokines or coagulation
factors, are able to activate the alter-
native complement pathway on their
membrane, leading to the release of
C5a fragments and further amplifi-
cation of the inflammatory response.10
Furthermore, the C5a receptor appea-
red to be essential for development of
MPO-ANCA crescentic glomerulo-
nephritis in an animal model.9 The
supposed role of C5a and its receptor
in AAV is represented in Figure 1.
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Figure 1 | Activation and effector mechanisms of complement in MPO-ANCA-mediated vasculitis. ANCA-mediated activation of cytokine-
primed neutrophils causes production of reactive oxygen species and release of proteolytic enzymes, resulting in endothelial damage.
Activation of neutrophils also induces the release of properdin (P) and factor B (B), both crucial for alternative pathway complement activation.
Complement system activation leads to the generation of C5a, which amplifies the inflammatory response via enhanced neutrophil recruitment
and priming of neutrophils for ANCA-mediated activation. (Adapted from: Van Timmeren MM, Heeringa P. Pathogenesis of ANCA-associated
vasculitis: recent insights from animal models. Curr Opin Rheumatol 2012; 24: 8–14.)
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It therefore seems logical to intervene
in the C5a–C5a receptor interaction in
patients with AAV. Indeed, a clinical
trial evaluating the safety and efficacy
of an inhibitor of the C5a receptor
(CCX168), a small molecule that is
orally administered, has been started in
patients with ANCA-associated renal
vasculitis (ClinicalTrials.gov identifier
NCT01363388). The results of this trial,
which are eagerly awaited, should
demonstrate whether intervention in
the complement system will become an
essential step in the early treatment of
patients with life-threatening AAV.
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Access to kidney transplantation
in Australia: does equal mean
equitable?
Fergus J. Caskey1 and Rommel Ravanan1
Sociodemographic gradients have been widely reported in end-stage
renal disease treatment, as in the general population. So should we be
relieved by the report from Grace et al. of no such gradient in access to
deceased donor kidney transplantation in Australia? Although the
authors have adjusted for the ‘competing risk’ of living kidney donor
transplantation, which is higher in higher socioeconomic groups, it feels
a little early to be reassured.
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Kidney transplantation offers patients
with end-stage renal disease the greatest
survival and quality-of-life opportunities,
with the best results observed in those
receiving kidneys from living donors.
In order for a patient to receive a kidney
transplant, a number of steps must be
successfully completed (Figure 1).1 First,
the potential recipient must receive
accurate, balanced information about
the treatment options available. Al-
though this sounds straightforward, it
relies on the treating clinician having the
communication skills to raise the topic in
a timely manner, provide appropriate
information about the various treatment
options, and identify potential barriers to
transplantation for that individual. None
of this can happen until the patient has
been referred to a nephrologist and, in
some settings, until he or she have been
referred by that nephrologist to a
transplant physician or surgeon. The
various components of the transplant
assessment need to be completed, each
of which introduces delays as well as
direct and indirect costs to the recipient.
Although many national organizations
have guidelines on suitability for kidney
transplantation, these are largely based
on expert opinion, and the final decision
remains highly subjective. Once the
patient is on the waiting list, organ
allocation protocols largely take over.
Living kidney donor (LKD) trans-
plantation introduces further potential
barriers, costs, and delays. Balanced,
informed information about the risks
and benefits of all options needs to
reach potential donors, who have to be
healthy enough to donate and finan-
cially secure enough not to be dis-
suaded by the threat to their income,
job, or future health-care costs.
It is in this context that we read the
interesting report from the Australia
and New Zealand Dialysis and Trans-
plant Registry (ANZDATA) on access to
kidney transplantation in Australia
(Grace et al.,2 this issue). Studying all
patients commencing renal replace-
ment therapy in Australia from 2000
to 2010 (n¼ 21,190), Grace et al. report
93% higher preemptive transplantation
rates for people living in the most
affluent areas. All preemptive trans-
plants were the result of LKD trans-
plantation, and this higher rate of LKD
transplantation persisted on to renal
replacement therapy, with those from
affluent areas having a 34% increased
chance of receiving an LKD transplant
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